Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §102 only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BABIC, CHRISTOPHER M | 1 | 60.7% | +22.5% |
| TICHY, JENNIFER M.H. | 1 | 65.2% | +33.8% |
| NOAKES, SUZANNE MARIE | 1 | 73.1% | +18.3% |
| ZHU, JIANJIAN | 1 | 59.7% | +82.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 53d overdue |
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | BABIC, CHRISTOPHER M | 38d overdue |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 2d overdue |
| 17909971 | SELECTABLE MARKER PROTEINS, EXPRESSION VECTORS, ENGINEERED CELLS AND EXTRACELLULAR VESICLES FOR THE PRODUCTION OF VIRUS-LIKE PARTICLES FOR THERAPEUTIC AND PROPHYLACTIC APPLICATIONS | NOAKES, SUZANNE MARIE | 27d |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1653 | 1 |
| 1656 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18011041 | Extracellular Vesicles Engineered to Be Loaded with Distinct RNA Cargo for Improved Therapeutic Efficacy | BABIC, CHRISTOPHER M | 1633 | §103 | Non-Final OA | 38d overdue | Pending | Dec 16, 2022 |
| 17906464 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | TICHY, JENNIFER M.H. | 1653 | §103 | Final Rejection | 53d overdue | Pending | Sep 15, 2022 |
| 17909971 | SELECTABLE MARKER PROTEINS, EXPRESSION VECTORS, ENGINEERED CELLS AND EXTRACELLULAR VESICLES FOR THE PRODUCTION OF VIRUS-LIKE PARTICLES FOR THERAPEUTIC AND PROPHYLACTIC APPLICATIONS | NOAKES, SUZANNE MARIE | 1656 | §102 | Non-Final OA | 27d | Pending | Sep 07, 2022 |
| 17608636 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | ZHU, JIANJIAN | 1631 | Other | Final Rejection | 2d overdue | Pending | Nov 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial